Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis

Citation
Rm. Fagugli et al., Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis, INT J ARTIF, 24(5), 2001, pp. 256-262
Citations number
34
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology
Journal title
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
ISSN journal
0391-3988 → ACNP
Volume
24
Issue
5
Year of publication
2001
Pages
256 - 262
Database
ISI
SICI code
0391-3988(200105)24:5<256:AGEPSF>2.0.ZU;2-C
Abstract
Background: Advanced glycation end products (AGE) accumulate in uremia and represent an important etiopathogenetic cause of morbidity in dialyzed pati ents. Conventional hemodialysis treatment seems to be ineffective in loweri ng AGE levels. We wished to investigate whether daily hemodialysis (DHD), a treatment that seems to result in better clinical condition in end-stage r enal disease patients, is effective in the reduction of these compounds. Methods: We evaluated 10 non-diabetic patients on standard hemodialysis (SH D = 3 x 4h/week) for more than 6 months by a crossover study. These patient s were assigned randomly to 6 months of DHD (6 x 2h/week) or 6 months of SH D. Then, they were switched to 6 months of the alternative treatment. At th e end of these two periods, we studied pentosidine-like AGE compounds by me asuring the total fluorescence at a wavelength characteristic for these sub stances: Ex: 335nm / Em:385nm; we also measured protein-linked pentosidine at the same time points. Finally we determined the AGE-related total fluore scence in the deproteinized serum of 13 uremic patients on peritoneal dialy sis (CAPD) and of 10 healthy controls. Results: Pre-HD AGE-related total fluorescence obtained after 6 months of D HD was significantly lower than that obtained with standard HD (DHD = 201.3 +/- 36.4 AU/ml vs. SHD = 267.5 +/- 141.4 AU/ml, p=0.03). The extraction ra te per minute of dialysis was slightly, but not significantly higher during DHD than SHD (0.29 +/- 0.11% vs. 0.23 +/- 0.04, p = 0.07). AGE-related tot al fluorescence pre-HD values in patients treated by SHD and DHD were about 20-fold higher than in control subjects. They did not differ from CAPD pat ients. The pre-dialysis level of protein-linked pentosidine was significant ly lower in DHD than in SHD (DHD = 16.12 +/- 4.71 pmol/mg protein, SHD = 22 .64 +/- 6.86 pmol/mg protein, p < 0.01). Conclusions: DHD showed a reduction in AGE-related total fluorescence, alth ough the mean value remained higher than in control subjects. DHD is also a ccompanied by a decrease in protein-linked pentosidine.